New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 18, 2013
09:27 EDTLIFE, RHHBY, TMO, GELife Technologies potential buyers could have better options, says Piper Jaffray
After Life Technologies (LIFE) said it hired two investment banks to aid in its annual strategic review, Piper Jaffray said it believes a takeover or leveraged buyout is potentially in the works. Piper said it sees several potential acquirers for Life, listing Roche (RHHBY), Thermo Fisher (TMO) and General Electric (GE) as possibly making strategic sense. However, Piper says the slower growing Research Consumables business makes up 43% of Life's revenue. As such, it believes an acquirer interested in the faster growing next-gen sequencing business has better options. Piper has a Neutral rating on shares of Life Technologies.
News For LIFE;RHHBY;TMO;GE From The Last 14 Days
Check below for free stories on LIFE;RHHBY;TMO;GE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 16, 2014
07:13 EDTGEGeneral Electric April volatility elevated into Q1 and revenue outlook
Subscribe for More Information
April 15, 2014
10:18 EDTGEGE Healthcare completes acquisition of CHCA Computer Systems
Subscribe for More Information
10:01 EDTGEGeneral Electric says Dan Janki to lead GE's Treasury operations
GE Chairman and CEO Jeff Immelt announced the appointment of Dan Janki to lead GEís Treasury operations, succeeding Kathy Cassidy, who is retiring later this year after 35 years of service to GE. Mark Begor, who currently leads GE Capitalís Real Estate business, will succeed Janki as president & CEO of GE Energy Management. Alec Burger, currently the North America leader for GE Capital Real Estate, will succeed Mark Begor as president & CEO of GE Capital Real Estate. The CEO appointments are effective immediately and the formal Treasury transition will be effective by the end of April.
09:02 EDTRHHBYRoche confirms FY outlook for low-to mid-single digit growth in sales
Subscribe for More Information
09:01 EDTRHHBYRoche reports Q1 sales CHF11.496B vs. CHF11.589B a year ago
Roche reported Q1 group sales rose 5% at constant exchange rates and fell 1% in Swiss francs compared to the prior year. Pharma sales were up 4%, with continued growth of Avastin, MabThera/Rituxan, Actemra/RoActemra and Herceptin compensating for expected decline in Xeloda sales, while Diagnostics division sales were up 7%. Roche CEO Severin Schwan said: ďBoth the Pharma and Diagnostics Divisions posted solid growth in the first quarter. I am particularly pleased with the strong uptake of our recently launched medicines Perjeta and Kadcyla for HER2-positive breast cancer."
08:23 EDTRHHBYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:19 EDTRHHBYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
06:32 EDTRHHBYPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
06:04 EDTGEGE CEO may give up leadership earlier than 20-year tenure, WSJ says
Subscribe for More Information
April 14, 2014
11:54 EDTGEGE reports Omnyx gets FDA clearance for digital manual read of HER2 slides
Subscribe for More Information
April 10, 2014
11:42 EDTRHHBYReport claims Tamiflu, Relenza do little to prevent the spread of flu
Subscribe for More Information
09:03 EDTGEGE to provide grid modernization solutions to Furnas
GEís Digital Energy business is providing Furnas and Triangulo Mineiro Transmissora/Geoenergia with the latest in protection and control equipment to ensure performance and quality for each of the utilityís grid modernization projects. Furnas is one of the biggest utilities in Latin America and is responsible for power transmission in south, southeast and mid west Brazil. These projects, which support the modernization of Brazilís grid, mark GEís entry into Brazilís ANEEL transmission auctions. The auctions were won in December 2013 by TMT, a collaborative utility composed of Furnas and FIP Milao, with Furnas being the largest participant at 49%.
April 9, 2014
09:10 EDTGEWal-Mart to purcahse energy-efficient LED ceiling lighting fixtures from GE
Subscribe for More Information
April 8, 2014
16:10 EDTRHHBYProthena says first human dosed in Phase 1 study of PRX002
Prothena (PRTA) announced the successful start of a Phase 1 clinical trial of its therapeutic monoclonal antibody candidate, PRX002, for the treatment of Parkinson's disease. Prothena has earned a $15M milestone payment from Roche (RHHBY) related to the initiation of this study. The initial Phase 1 clinical trial of PRX002 is a randomized, double-blind, placebo-controlled, single ascending dose study in healthy subjects. It is designed to assess PRX002 for safety, tolerability, pharmacokinetics and immunogenicity. As previously announced in December 2013, Prothena entered into a worldwide collaboration with Roche to develop and commercialize antibodies that target α-synuclein, including PRX002. Including the current milestone payment, Prothena has now achieved a total of $45M through its worldwide PRX002 collaboration with Roche.
11:03 EDTRHHBYPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
09:07 EDTGEGE Healthcare receives FDA clearance of its Q.Clear technology
GE Healthcare, a unit of General Electric, announced that it received U.S. FDA 510 clearance of its Q.Clear technology -- technology that can provide up to two times improvement in both quantitative accuracy and image quality in PET/CT imaging. This is an innovative new tool for clinicians across the entire care continuum including diagnosis, staging, treatment planning, and treatment assessment.
08:03 EDTGEGE unit provides $50M loan for Illinois power plant
Subscribe for More Information
07:24 EDTGEPR News to hold a conference
Subscribe for More Information
April 7, 2014
07:39 EDTGEBloomberg to hold a summit
The Future of Energy Summit 2014 is being held in New York on April 7-9.
06:07 EDTRHHBYRoche acquires IQuum for $450M
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use